Conor Walsh
Senior Director, Biopharma Insights
The cardiovascular drug market is currently in a state of transition. Despite the recent launches of generic versions of the most highly prescribed cardiovascular agents, the robust pipeline—which includes forecasted blockbusters such as the recently-launched PCSK9 inhibitors for dyslipidemia and Novartis’s Entresto for heart failure—demonstrates that drug developers remain interested in this space.”
Conor Walsh, MSc, PhD, is a Senior Director in the Cardiovascular, Metabolic, and Renal Disorders team at Decision Resources Group. In this role, he leads a team of 7 analysts and 1 director, covering a range of indications with a focus on the cardiovascular and metabolic space.
Prior to joining Decision Resources, he worked at Medical Marketing Research International. Dr. Walsh holds an MSc in Bioinformatics and a PhD in Cardiac Structural Biology, both from the University of Manchester, United Kingdom. For his doctoral work, he studied the molecular mechanisms underlying heart failure. Dr. Walsh earned his BSc in Biotechnology with first-class honors from the National University of Ireland in Galway.
Available as a speaker
Contact Us About Your EventRelated Analysts
-
Bill Melville
Principal Analyst -
Andrew Merron, Ph.D
Therapy Leader
Connect